Know Labs Crecimiento futuro

Future controles de criterios 0/6

Se prevé que los beneficios de Know Labs disminuyan a un ritmo anual de 13.7%, mientras que sus ingresos anuales crecerán a un ritmo de 150.1% por año. Se espera que el BPA disminuya en un 15.9% al año.

Información clave

-13.7%

Tasa de crecimiento de los beneficios

-15.9%

Tasa de crecimiento del BPA

Crecimiento de los beneficios de Medical Equipment	17.1%
Tasa de crecimiento de los ingresos	150.1%
Rentabilidad financiera futura	n/a
Cobertura de analistas	Low
Última actualización	15 Aug 2024

Actualizaciones recientes sobre el crecimiento futuro

No hay actualizaciones

Recent updates

Previsiones de crecimiento de beneficios e ingresos

NYSEAM:KNW - Estimaciones futuras de los analistas y datos financieros pasados (USD Millions)
Fecha	Ingresos	Beneficios	Flujo de caja libre	Flujo de caja operativo	Núm. de analistas medio
9/30/2026	6	-22	N/A	-20	1
9/30/2025	N/A	-19	N/A	-15	1
9/30/2024	N/A	-17	-13	-13	N/A
6/30/2024	N/A	-16	-11	-11	N/A
3/31/2024	N/A	-21	-11	-11	N/A
12/31/2023	N/A	-20	-11	-11	N/A
9/30/2023	N/A	-20	-10	-10	N/A
6/30/2023	N/A	-23	-12	-12	N/A
3/31/2023	N/A	-17	-12	-12	N/A
12/31/2022	0	-19	-8	-8	N/A
9/30/2022	4	-20	-8	-7	N/A
6/30/2022	4	-22	-6	-5	N/A
3/31/2022	4	-26	-6	-5	N/A
12/31/2021	4	-25	-8	-7	N/A
9/30/2021	N/A	-25	-7	-7	N/A
6/30/2021	N/A	-22	-6	-6	N/A
3/31/2021	N/A	-18	-6	-5	N/A
12/31/2020	0	-16	-5	-5	N/A
9/30/2020	0	-14	-4	-4	N/A
6/30/2020	0	-12	-4	-4	N/A
3/31/2020	1	-12	-4	-4	N/A
12/31/2019	1	-10	-3	-3	N/A
9/30/2019	2	-8	-3	-3	N/A
6/30/2019	2	-5	-2	-2	N/A
3/31/2019	3	-4	-2	-2	N/A
12/31/2018	4	-3	-1	-1	N/A
9/30/2018	4	-3	-1	-1	N/A
6/30/2018	5	-3	N/A	-1	N/A
3/31/2018	5	-2	N/A	-1	N/A
12/31/2017	5	-2	N/A	-1	N/A
9/30/2017	5	-4	N/A	-1	N/A
6/30/2017	5	-4	N/A	-2	N/A
3/31/2017	6	-3	N/A	-2	N/A
12/31/2016	6	-2	N/A	-3	N/A
9/30/2016	6	-2	N/A	-3	N/A
6/30/2016	6	-3	N/A	-2	N/A
3/31/2016	6	-4	N/A	-1	N/A
12/31/2015	6	-1	N/A	0	N/A
9/30/2015	6	-3	N/A	0	N/A
6/30/2015	7	0	N/A	-1	N/A
3/31/2015	7	1	N/A	-1	N/A
12/31/2014	8	-3	N/A	-2	N/A
9/30/2014	8	-1	N/A	-1	N/A
6/30/2014	8	-2	N/A	-2	N/A
3/30/2014	8	-6	N/A	-3	N/A
12/31/2013	8	-7	N/A	-3	N/A

Previsiones de crecimiento futuro de los analistas

Ingresos vs. Tasa de ahorro: Se prevé que KNW siga sin ser rentable en los próximos 3 años.

Beneficios vs. Mercado: Se prevé que KNW siga sin ser rentable en los próximos 3 años.

Beneficios de alto crecimiento: Se prevé que KNW siga sin ser rentable en los próximos 3 años.

Ingresos vs. Mercado: Se prevé que KNW no tenga ingresos el año que viene.

Ingresos de alto crecimiento: Se prevé que KNW no tenga ingresos el año que viene.

Previsiones de crecimiento de los beneficios por acción

Rentabilidad financiera futura

ROE futura: Datos insuficientes para determinar si la rentabilidad financiera de KNW se prevé que sea elevada dentro de 3 años.

Know Labs Crecimiento futuro

Future controles de criterios 0/6

Información clave

Actualizaciones recientes sobre el crecimiento futuro

Recent updates

Know Labs, Inc Announces Executive Appointments

Know Labs Receives Non Compliance Letter from NYSE American Regarding Sections 1003(a)(ii) and 1003(a)(iii)

High number of new and inexperienced directors

Know Labs, Inc. Announces Board and Committee Changes

Know Labs, Inc. has completed a Composite Units Offering in the amount of $3.445 million.

Know Labs, Inc., Annual General Meeting, Sep 26, 2024

Know Labs, Inc. Publishes Clinical Results in Leading Diabetes Journal

Know Labs, Inc. Announces Further Interim Results from a Clinical Research Study

Know Labs, Inc. Announces the Appointment of Chris Somogyi as President, International

Know Labs, Inc. to Present Clinical Research At the 2024 American Association of Clinical Endocrinology Annual Meeting

Know Labs, Inc. has filed a Follow-on Equity Offering in the amount of $5 million.

Know Labs, Inc. Announces Interim Results from its Most Recent Clinical Research Study

Know Labs, Inc. Announces Board Appointments

Know Labs, Inc. Expands Board of Directors

Know Labs, Inc. has completed a Follow-on Equity Offering in the amount of $7 million.

Know Labs, Inc., Annual General Meeting, Sep 22, 2023

Know Labs, Inc. Demonstrates Improved Accuracy of Machine Learning Model for Non-Invasive Glucose Monitor

Know Labs Completes Build of Portable Generation 1 Prototype for Non-Invasive Glucose Monitoring

Know Labs, Inc. Furthers External Validation of Bio-RFID(TM) Technology with Study Published in Sensors Journal

Know Labs, Inc. Study Validates Technical Feasibility of Its Novel Sensor for Non-Invasive Glucose Monitoring

Know Labs, Inc. Announces Changes to Executive Leadership Team

Know Labs, Inc. Announces Management Changes

Know Labs Common Stock Deleted from OTC Equity

Know Labs, Inc. has completed an IPO in the amount of $7.2 million.

Know Labs, Inc., Annual General Meeting, Sep 15, 2022

Know Labs, Inc. Announces Executive Appointments

Know Labs, Inc. Announces Executive Appointments

Know Labs Outlines Preparations for Pre-Submission Meeting with FDA

Know Labs, Inc. announced delayed 10-Q filing

Know Labs, Inc. Receives IRB Approval to Begin Internal Clinical Trial of Non-Invasive Glucose Monitoring Technology Bio-RFID™

Know Labs, Inc. Announces Introduction of New KnowU™ Diagnostic Device

Know Labs Receives New Patent for Its Non-Invasive Diagnostic Technology Platform, Bringing Patents Issued and Pending to Nearly 60

Know Labs Announces Successful Results from Pre-Clinical Study Validating Bio-RFID™ Platform Technology

Know Labs, Inc. announced that it has received $14.279 million in funding

Texas Biomedical Research Institute Issues Preliminary Results for Know Labs, Inc.'s Particle Bulb's Ability to Inactivate the SARS-CoV-2 Virus

Previsiones de crecimiento de beneficios e ingresos

Previsiones de crecimiento futuro de los analistas

Previsiones de crecimiento de los beneficios por acción

Rentabilidad financiera futura

Descubre empresas en crecimiento